Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials

References

• United Nations Office on Drugs and Crime. World drug report 2019: booklet 2. Vienna: United Nations Publication; 2019 [accessed 2020 June 1]. https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_2_DRUG_DEMAND.pdf.
   Google Scholar
• Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82. doi:10.1016/j.drugalcdep.2018.12.030. Cited in: PMID: 30784952.
   PubMed Web of Science ®Google Scholar
• Torrens M, Mestre-Pinto JI, Domingo-Salvany A. Comorbidity of substance use and mental disorders in Europe. Luxembourg: Publications office of the European Union; 2015 [accessed 2020 June 1]. http://www.emcdda.europa.eu/system/files/publications/1988/TDXD15019ENN.pdf.
   Google Scholar
• Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan Z. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat. 2017;13:1399–408. doi:10.2147/NDT.S129480. Cited in: PMID: 28579787.
   PubMed Web of Science ®Google Scholar
• Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10:93–103. doi:10.1097/ADM.0000000000000193. Cited in: PMID: 26808307.
   PubMed Web of Science ®Google Scholar
• Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999;156:2017. doi:10.1176/ajp.156.12.2017. Cited in: PMID: 10588427.
   PubMed Web of Science ®Google Scholar
• Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28:593–95. doi:10.1097/JCP.0b013e31818638a4. Cited in: PMID: 18794671.
   PubMed Web of Science ®Google Scholar
• Serafini G, Adavastro G, Canepa G, De Berardis D, Valchera A, Pompili M, Nasrallah H, Amore M. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19:E2410. doi:10.3390/ijms19082410. Cited in: PMID: 30111745.
   PubMed Web of Science ®Google Scholar
• Peciña M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta JK. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24:576–87. doi:10.1038/s41380-018-0117-2. Cited in: PMID: 29955162.
   PubMed Web of Science ®Google Scholar
• Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36:195–206. doi:10.1016/j.tins.2012.11.002. Cited in: PMID: 23219016.
   PubMed Web of Science ®Google Scholar
• Fingleton N, Matheson C, Jaffray M. Changes in mental health during opiate replacement therapy: a systematic review. Drugs. 2015;22:1–18.
   Web of Science ®Google Scholar
• Feelemyer JP, Des Jarlais DC, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251–58. doi:10.1016/j.drugalcdep.2013.10.011. Cited in: PMID: 24200104.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, eds. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.
   Google Scholar
• Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, Harrison S, Janmohamed A, Anis AH, Krausz M, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73:447–55. doi:10.1001/jamapsychiatry.2016.0109. Cited in: PMID: 27049826.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency. Subst Abuse Treat Prev Policy. 2015;10:3. doi:10.1186/1747-597X-10-3. Cited in: PMID: 25619263.
   PubMed Web of Science ®Google Scholar
• Van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, Van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327:310. doi:10.1136/bmj.327.7410.310. Cited in: PMID: 12907482.
   PubMed Web of Science ®Google Scholar
• March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31:203–11. doi:10.1016/j.jsat.2006.04.007. Cited in: PMID: 16919749.
   PubMed Web of Science ®Google Scholar
• Reimer J, Verthein U, Karow A, Schäfer I, Naber D, Haasen C. Physical and mental health in severe opioid‐dependent patients within a randomized controlled maintenance treatment trial. Addiction. 2011;106:1647–55. doi:10.1111/j.1360-0443.2011.03463.x. Cited in: PMID: 21489005.
   PubMed Web of Science ®Google Scholar
• Karow A, Reimer J, Schäfer I, Krausz M, Haasen C, Verthein U. Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence. Drug Alcohol Depend. 2010;112:209–15. doi:10.1016/j.drugalcdep.2010.06.009. Cited in: PMID: 20728288.
   PubMed Web of Science ®Google Scholar
• Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191:55–62. doi:10.1192/bjp.bp.106.026112. Cited in: PMID: 17602126.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361:777–86. doi:10.1056/NEJMoa0810635. Cited in: PMID: 19692689.
   PubMed Web of Science ®Google Scholar
• Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, Roubaix JD, Charlier C, Lemaitre A, Ansseau M. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 2015;21:179–87. doi:10.1159/000369337. Cited in: PMID: 25832522.
   PubMed Web of Science ®Google Scholar
• Metrebian N, Groshkova T, Hellier J, Charles V, Martin A, Forzisi L, Lintzeris N, Zador D, Williams H, Carnwath T, et al. Drug use, health and social outcomes of hard‐to‐treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction. 2015;110:479–90. doi:10.1111/add.12748. Cited in: PMID: 25251885.
   PubMed Web of Science ®Google Scholar
• Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375:1885–95. doi:10.1016/S0140-6736(10)60349-2. Cited in: PMID: 20511018.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Strang J, Metrebian N, Byford S, Hallam C, Lee S, Zador D. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J. 2006;3:28. doi:10.1186/1477-7517-3-28. Cited in: PMID: 17002810.
   PubMedGoogle Scholar
• Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow‐release morphine and methadone for opioid maintenance therapy. Addiction. 2005;100:1101–09. doi:10.1111/j.1360-0443.2005.001128.x. Cited in: PMID: 16042640.
   PubMed Web of Science ®Google Scholar
• Winklbaur B, Jagsch R, Ebner N, Thau K, Fischer G. Quality of life in patients receiving opioid maintenance therapy. A comparative study of slow-release morphine versus methadone treatment. Eur Addict Res. 2008;14:99–105. doi:10.1159/000113724. Cited in: PMID: 18334820.
   PubMed Web of Science ®Google Scholar
• Verthein U, Beck T, Haasen C, Reimer J. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res. 2015;21:97–104. doi:10.1159/000368572. Cited in: PMID: 25427944.
   PubMed Web of Science ®Google Scholar
• Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, Ruckes C, Reimer J. Maintenance treatment for opioid dependence with slow‐release oral morphine: a randomized cross‐over, non‐inferiority study versus methadone. Addiction. 2014;109:617–26. doi:10.1111/add.12440. Cited in: PMID: 24304412.
   PubMed Web of Science ®Google Scholar
• Robertson JR, Raab GM, Bruce M, McKenzie JS, Storkey HR, Salter A. Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: a randomized controlled trial. Addiction. 2006;101:1752–59. doi:10.1111/j.1360-0443.2006.01603.x. Cited in: PMID: 17156174.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend. 1993a;33:105–17. doi:10.1016/0376-8716(93)90052-R. Cited in: PMID: 8261875.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993b;119:23–27. doi:10.7326/0003-4819-119-1-199307010-00004. Cited in: PMID: 8498759.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Useful predictors of outcome in methadone-treated patients: results from a controlled clinical trial with three doses of methadone. J Maint Addict. 1998;1:15–28. doi:10.1300/J126v01n03_05.
   Google Scholar
• Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39–50. doi:10.1016/S0376-8716(00)80006-X. Cited in: PMID: 10821988.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol. 1996;16:58–67. doi:10.1097/00004714-199602000-00010. Cited in: PMID: 8834420.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025–30. Cited in: PMID: 8010359.
   PubMed Web of Science ®Google Scholar
• Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19:510–13. doi:10.1016/j.eurpsy.2004.09.002. Cited in: PMID: 15589713.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double‐blind trial with 405 opioid‐dependent patients. Addiction. 2003;98:441–52. doi:10.1046/j.1360-0443.2003.00335.x. Cited in: PMID: 12653814.
   PubMed Web of Science ®Google Scholar
• Neri S, Bruno CM, Pulvirenti D, Malaguarnera M, Italiano C, Mauceri B, Abate G, Cilio D, Calvagno S, Tsami A, et al. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology. 2005;179:700–04. doi:10.1007/s00213-005-2239-x. Cited in: PMID: 15806416.
   PubMed Web of Science ®Google Scholar
• Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction. 2002;97:533–42. doi:10.1046/j.1360-0443.2002.00090.x. Cited in: PMID: 12033654.
   PubMed Web of Science ®Google Scholar
• Dunlop AJ, Brown AL, Oldmeadow C, Harris A, Gill A, Sadler C, Ribbons K, Attia J, Barker D, Ghijben P, et al. Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. Drug Alcohol Depend. 2017;174:181–91. doi:10.1016/j.drugalcdep.2017.01.016. Cited in: PMID: 28371689.
   PubMed Web of Science ®Google Scholar
• Streck JM, Ochalek TA, Badger GJ, Sigmon SC. Interim buprenorphine treatment during delays to comprehensive treatment: changes in psychiatric symptoms. Exp Clin Psychopharmacol. 2018;26:403–09. doi:10.1037/pha0000199. Cited in: PMID: 29939049.
   PubMed Web of Science ®Google Scholar
• Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393:778–90. doi:10.1016/S0140-6736(18)32259-1. Cited in: PMID: 30792007.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898. Cited in: PMID: 31462531.
   PubMed Web of Science ®Google Scholar
• Müller JM, Postert C, Beyer T, Furniss T, Achtergarde S. Comparison of eleven short versions of the symptom checklist 90-revised (SCL-90-R) for use in the assessment of general psychopathology. J Psychopathol Behav Assess. 2010;32:246–54. doi:10.1007/s10862-009-9141-5.
   Web of Science ®Google Scholar
• Schaefer A, Brown J, Watson CG, Plemel D, DeMotts J, Howard MT, Petrik N, Balleweg BJ, Anderson D. Comparison of the validities of the Beck, Zung, and MMPI depression scales. J Consult Clin Psychol. 1985;53:415–18. doi:10.1037/0022-006X.53.3.415. Cited in: PMID: 4008725.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Savitz KL. The SCL-90-R, brief symptom inventory, and matching clinical rating scales. In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment. Mahwah: Lawrence Erlbaum Associates Publishers; 1999. p. 679–724.
   Google Scholar
• Prinz U, Nutzinger DO, Schulz H, Petermann F, Braukhaus C, Andreas S. Comparative psychometric analyses of the SCL-90-R and its short versions in patients with affective disorders. BMC Psychiatry. 2013;13:104. doi:10.1186/1471-244X-13-104. Cited in: PMID: 23537095.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32:959–76. doi:10.1017/S0033291702006074. Cited in: PMID: 12214795.
   PubMed Web of Science ®Google Scholar
• Mäkelä K. Studies of the reliability and validity of the addiction severity index. Addiction. 2004;99:398–410. doi:10.1111/j.1360-0443.2003.00665.x. Cited in: PMID: 15049734.
   PubMed Web of Science ®Google Scholar
• Bobes J, Garcia-Portilla P, Saiz PA, Bascaran T, Bousono M. Quality of life measures in schizophrenia. Eur Psychiatry. 2005;20:S313–317. doi:10.1016/S0924-9338(05)80182-8. Cited in: PMID: 16459242.
   PubMed Web of Science ®Google Scholar
• Hewitt J. Critical evaluation of the use of research tools in evaluating quality of life for people with schizophrenia. Int J Ment Health Nurs. 2007;16:2–14. doi:10.1111/j.1447-0349.2006.00438.x. Cited in: PMID: 17229269.
   PubMed Web of Science ®Google Scholar
• Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PloS One. 2014;9:e99682. doi:10.1371/journal.pone.0099682. Cited in: PMID: 24992266.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, Atkins D, Kunz R, Montori V, Jaeschke R, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66:151–57. doi:10.1016/j.jclinepi.2012.01.006. Cited in: PMID: 22542023.
   PubMed Web of Science ®Google Scholar
• Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double‐blind, double‐dummy comparison study. Addiction. 2006;101:275–81. doi:10.1111/j.1360-0443.2006.01321.x. Cited in: PMID: 16445556.
   PubMed Web of Science ®Google Scholar
• Nikoo M, Moazen‐Zadeh E, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Givaki R, et al. Comparing opium tincture and methadone for medication‐assisted treatment of patients with opioid use disorder: protocol for a multicenter parallel group noninferiority double‐blind randomized controlled trial. Int J Methods Psychiatr Res. 2019;28:e1768. doi:10.1002/mpr.1768. Cited in: PMID: 30714249.
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Branstetter SA, Mikulich SK. A controlled comparison of the buprenorphine-naloxone tablet and methadone for opioid maintenance treatment: interim results. In: Harris LS, editor. Problems of drug dependence 1999: proceedings of the 61st annual scientific meeting, the college on problems of drug dependence, Inc. Vol. 180. NIDA Res Monogr; 1999. p. 161.
   Google Scholar
• Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2008.
   Google Scholar
• Schafer I, Eiroa-Orosa FJ, Verthein U, Dilg C, Hassen C, Reimer J. Effects of psychiatric comorbidity on treatment outcome in patients undergoing diamorphine or methadone maintenance treatment. Psychopathology. 2010;43:88–95. doi:10.1159/000274177. Cited in: PMID: 20068379.
   PubMed Web of Science ®Google Scholar
• Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates‐Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25:603–09. doi:10.1111/ajad.12454. Cited in: PMID: 28051841.
   PubMed Web of Science ®Google Scholar
• Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin‐dependent individuals. Cochrane Database Syst Rev. 2011;12:CD003410. doi:10.1002/14651858.ED000094. Cited in: PMID: 221613.
   PubMed Web of Science ®Google Scholar